Progesterone vaginal

Baker, E. R., Best, R. G., Manfredi, R. L., Demers, L. M., and Wolf, G. C. 1995. Efficacy of progesterone vaginal suppositories in alleviation of nervous symptoms in patients with premenstrual syndrome. Journal of Assisted Reproduction and Genetics 12 205-209. 

Mahaguna, V., McDermott, J. M., Zhang, F., and Ochoa, F. (2004), Investigation of product quality between extemporaneously compounded progesterone vaginal... 

Diaz S, Reyes MV, Zepeda A, et al. Norplant implants and progesterone vaginal rings do not affect maternal bone turnover and density during lactation and after weaning. Hum Reprod 1999 11 2499-2505. 

Conventional vaginal delivery systems include tablets, foams gels, suspensions, and pessaries. Mucoadhesive gel formulations based on polycarbophil have been reported to remain 3 to 4 days at the vaginal tissue, providing an excellent vehicle for the delivery of progesterone and nonoxynol-9 [66]. 

Oestradiol and progesterone regulate the structural and functional changes in oviducts, uterus, cervix and vagina that occur during the menstrual cycle. They provide conditions in the oviduct for the upward motility of sperm, and the downward movement of ova, and also conditions favourable for fertilisation in the oviduct and implantation in the uterus. Another effect is to stimulate vaginal secretions. 

Pouly JL, Bassil S, Frydman R, Hedon B, Nicollet B, Prada Y, Antoine JM, Zambrano R, Donnez J. Luteal support after in-vitro fertilization Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Hum Reprod 1996 ll(10) 2085-9. 

Warren MP, Biller BM, Shangold MM. A new clinical option for hormone replacement therapy in women with secondary amenorrhea effects of cyclic administration of progesterone from the sustained-release vaginal gel Crinone (4% and 8%) on endometrial morphologic features and withdrawal bleeding. Am J Obstet Gynecol 1999 180(1 Pt l) 42-8. 

Ng EHY, Miao B, Cheung W, Ho P-C. A randomised comparison of side effects and patient inconvenience of two vaginal progesterone formulations used for luteal support in in vitro fertilisation cycles. Eur J Obstet Gynecol Reprod Biol 2003 111 50-4. 

Miles, R.A., et al. 1994. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes A comparative study. Fertil Steril 62 485. 

Cicinelli, E., et al. 2000. Mechanisms of uterine specificity of vaginal progesterone. Hum Reprod 15 159. 

Massai, R., et al. 1999. Pre-registration study on the safety and contraceptive efficacy of a progesterone-releasing vaginal ring on Chilean nursing women. Contraception 60 9. 

---